Panelists discuss how circulating tumor DNA (ctDNA) testing serves as a complementary tool to traditional imaging in challenging colorectal cancer cases, offering molecular-level insights that can detect disease recurrence earlier, resolve ambiguous radiographic findings, and inform treatment decisions when conventional assessment methods yield inconclusive results.